Skip to main content
Funded Studies

Farnesoid X Receptor as a Target to Reduce Meuroinflammation

Study Rationale:
Although the precise mechanism(s) of neurodegeneration in Parkinson's disease (PD) are unknown, evidence suggests that neuroinflammation is an important contributor. In this study, we will use pre-clinical models of PD to determine whether existing drugs targeting the farnesoid x (a type of hormone) receptor can reduce inflammation and protect dopamine neurons.

This study hypothesizes that drugs targeting the farnesoid x receptor that are currently in clinical trials for other purposes will reduce neuroinflammation in pre-clinical models of PD.

Study Design:
We will use two pre-clinical models of PD that have significant inflammatory components. Existing drugs/compounds that target the farnesoid x receptor will be administered to these models to determine whether they can reduce inflammation and protect dopamine neurons.

Impact on Diagnosis/Treatment of Parkinson's disease:
In one or two sentences, explain how the project holds potential to impact the way Parkinson's is diagnosed and/or treated. Approximately 50 words

Next Steps for Development:
If our experiments are successful, therapies may progress to clinical trials for Parkinson's more rapidly, as they have been in clinical trials for other conditions.


  • Jason R. Richardson, PhD, MS, DABT

    Rootstown, OH United States

Discover More Grants

Search by Related Keywords

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.